As a fresh cluster of Nipah virus (NiV) infections emerges in India’s West Bengal state, health authorities worldwide are monitoring the situation closely.
The deadly zoonotic virus, first identified in 1998, remains a high-priority pathogen for the World Health Organization (WHO) due to its high fatality rate, potential for human-to-human transmission, and lack of approved vaccines or specific treatments.
In January 2026, at least five confirmed cases have been reported in West Bengal primarily among healthcare workers at a private hospital in Barasat near Kolkata marking the state’s first outbreak in 19 years. Authorities have quarantined nearly 100 contacts, with extensive testing yielding mostly negative results so far. The outbreak has prompted heightened airport screenings in countries like Thailand, Nepal, and Taiwan, reminiscent of COVID-19 protocols, as travelers from affected areas face monitoring ahead of major holidays like China’s Lunar New Year.

Here are four essential things to understand about Nipah virus in the current context of 2026:

1. High Fatality Rate and No Cure or Vaccine Available
Nipah virus infection carries one of the highest case fatality rates among known pathogens, estimated at 40% to 75% depending on the outbreak, surveillance quality, and clinical care. The virus causes severe respiratory illness or encephalitis (brain inflammation), leading to symptoms such as fever, headache, vomiting, dizziness, and in severe cases, coma or death. There are currently no licensed vaccines or antiviral drugs specifically targeting Nipah. Supportive care is the mainstay of treatment, though experimental approaches like the antiviral Remdesivir have been used in the ongoing West Bengal cases. The WHO lists Nipah among its top priority diseases for research and development, alongside Ebola and COVID-19, due to its epidemic potential.
2. Zoonotic Origins and Transmission Routes
Nipah is a bat-borne virus, with fruit bats (Pteropus species) serving as the natural reservoir. Spillover to humans typically occurs through consumption of raw date palm sap contaminated by bat saliva or urine, or direct contact with infected pigs (as seen in the 1998 Malaysia-Singapore outbreak). Once in humans, it can spread person to person via close contact with bodily fluidparticularly in healthcare settings, as evidenced by the current nosocomial (hospital-acquired) cluster in West Bengal, where nurses and other staff were infected after treating patients. Contaminated food has also been implicated in past outbreaks. Unlike airborne viruses like COVID-19, Nipah transmission requires close, prolonged exposure, which has helped contain most incidents to localized clusters.
3. Recurring Threat in Endemic Regions of South Asia
India has seen sporadic but recurrent Nipah outbreaks since 2001, with West Bengal reporting cases in 2001 and 2007, and the southern state of Kerala emerging as a hotspot in recent years (major outbreaks in 2018 with 17 deaths out of 19 cases, and additional incidents in 2023 and mid-2025). Experts now classify both Kerala and West Bengal as endemic zones for the virus. The 2026 West Bengal outbreak, the first there in nearly two decades, began after an initial death from an undiagnosed illness, followed by infections among responding healthcare workers. Bangladesh remains another high-risk area with near-annual outbreaks linked to date palm sap consumption. No cases have been reported outside South Asia in this current event, though global concern has risen due to travel links.
4. Progress in Preparedness and Research
While no countermeasures are licensed yet, 2026 marks advances in Nipah preparedness. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding a robust R&D portfolio, including the world’s most advanced vaccine candidate,a ChAdOx-based shot from the University of Oxford that entered Phase II trials in Bangladesh in late 2025. A promising monoclonal antibody (mAb) candidate, MBP1F5, is slated for early-to-mid-stage trials in an affected country this year. Regulatory pathways are being accelerated to potentially license a vaccine within the next five years. In the meantime, public health responses focus on rapid contact tracing, isolation, infection control in hospitals, and avoiding high risk behaviors like consuming raw sap in endemic areas. The current outbreak is described as “not major” and contained, but it underscores the need for vigilance in bat-inhabited regions.

Health officials emphasize that while Nipah poses a serious risk, its limited transmission dynamics make large-scale epidemics less likely than with respiratory viruses. Travelers to or from affected areas in India are advised to monitor for symptoms (fever, headache, breathing difficulties) for up to 21 days post-exposure and seek immediate medical care if unwell. No imported cases have been detected in regions like China, Hong Kong, or elsewhere as of late January 2026, but enhanced screening continues at key airports.
The Nipah situation serves as a reminder of the ongoing threat from emerging zoonotic diseases in a world of increasing human-animal interface. Authorities urge calm, rapid reporting, and adherence to preventive measures to keep this deadly virus in check.